A phase II trial of pyrazoloacridine (PZA) in squamous carcinoma of the cervix--a Gynecologic Oncology Group Study.
OBJECTIVE
The Gynecologic Oncology Group performed a Phase II study to determine the response rate of Pyrazoloacridine (PZA) in patients with advanced, persistent or recurrent squamous carcinoma of the cervix.


METHODS
PZA was administered at a dose of 750 mg/m2 intravenously over three hours every three weeks.


RESULTS
Among 21 evaluable patients, there were no complete and one (4.2%) partial response. The major toxicities were hematologic.


CONCLUSIONS
PZA at the dose and schedule employed has insignificant activity in this population.
Plaxe
S C
SC
Gynecologic Oncology, University of California, San Diego, USA.
Blessing
J A
JA
Lucci
J A
JA
Hurteau
J A
JA
D000166:Acridines / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D011720:Pyrazoles / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000473:pathology
D000166:Acridines; D000970:Antineoplastic Agents; D011720:Pyrazoles; C064541:NSC 366140